SNCE

Science 37 Holdings, Inc. Common Stock

SNCE

Market cap $34.7M

Delisted

SNCE was delisted on the 11th of March, 2024.

Back to rankings

About: Science 37 Holdings Inc is engaged in the development of new and innovative treatments that impact patient lives. It enables universal access to patients and providers for clinical trials. Its Operating System is fused with networks of telemedicine investigators, mobile nurses, remote coordinators, patient communities and connected devices.

Employees: 460

Healthcare Diagnostics & Research

Financial journalist opinion

Science 37 Unveils New Corporate Headquarters in Research Triangle Park, NC

MORRISVILLE, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Science 37 , a leader in enhancing patient access to clinical trials, today announced the grand opening of its new, 19,000-square-foot corporate headquarters in Morrisville, North Carolina, in the heart of Research Triangle Park.

Science 37 Unveils New Corporate Headquarters in Research Triangle Park, NC

Science 37 Quickly Impacts Performance in Under-Enrolling Clinical Trials

RESEARCH TRIANGLE PARK, N.C., June 27, 2024 (GLOBE NEWSWIRE) -- Science 37 , a leader in enhancing patient access to clinical trials, has been added to over 20 studies that were lagging in recruitment, helping them to trend back towards their projected targets.

Science 37 Quickly Impacts Performance in Under-Enrolling Clinical Trials

CORRECTION-- Science 37 Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial

RESEARCH TRIANGLE PARK, N.C., June 12, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Science 37, Inc., please note that the first sentence of the second paragraph has been revised.

CORRECTION-- Science 37 Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial

Science 37 Metasite™ Undergoes Successful FDA Inspection, Marking Major Milestone in Virtual Site Quality Assurance and Compliance

RESEARCH TRIANGLE PARK, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. today announced the preliminary outcome of its recent FDA Inspection focusing on critical areas and documentation.

Science 37 Metasite™ Undergoes Successful FDA Inspection, Marking Major Milestone in Virtual Site Quality Assurance and Compliance

Science 37 Wins 2024 MedTech Breakthrough Award for “Clinical Efficiency Innovation”

Science 37 announces its selection as the winner of the “Clinical Efficiency Innovation Award” in the 8th annual MedTech Breakthrough Awards program.

Science 37 Wins 2024 MedTech Breakthrough Award for “Clinical Efficiency Innovation”

Science 37 Delivers 22x Faster Enrollment than Traditional Methods in Phase 3 Asthma Clinical Trial

RESEARCH TRIANGLE PARK, N.C., May 02, 2024 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. today disclosed the latest enrollment figures resulting from its Metasite™ and Patient Recruitment partnership with a leading biotech company whose asthma drug is currently undergoing a Phase 3 clinical trial.

Science 37 Delivers 22x Faster Enrollment than Traditional Methods in Phase 3 Asthma Clinical Trial

Science 37 Provides Fully Consented Patients to Sites to Supplement Enrollment

RESEARCH TRIANGLE PARK, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc., the clinical research industry's leading MetasiteTM, today announced the launch of a stand-alone Patient Recruitment Solution to deliver patients to sites that are eligible, medically reviewed, and fully consented.

Science 37 Provides Fully Consented Patients to Sites to Supplement Enrollment

eMed completes tender offer for all outstanding shares of Science 37

MIAMI , March 12, 2024 /PRNewswire/ -- eMed, LLC ("eMed") today announced the successful completion of the previously announced tender offer by its wholly-owned subsidiary, Marlin Merger Sub Corporation ("Purchaser"), for all the outstanding shares of common stock, par value $0.0001 per share, of Science 37 Holdings, Inc. (NASDAQ: SNCE) ("Science 37") at a price of USD 5.75 per share. Continental Stock Transfer & Trust Company, the depositary for the tender offer, has advised Purchaser that, as of 12:00 Midnight, New York City time, at the end of the day of Monday, March 11, 2024 (the "Expiration Time"), the expiration of the tender offer, (i) 4,715,950 shares were validly tendered and not withdrawn in the tender offer, representing approximately 77.8% of Science 37's outstanding shares of common stock, and (ii) notices of guaranteed delivery had been delivered with respect to 76,755 additional shares, representing approximately 1.3% of the outstanding shares.

eMed completes tender offer for all outstanding shares of Science 37

SCIENCE 37 HOLDINGS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Science 37 Holdings, Inc. - SNCE

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Science 37 Holdings, Inc. (NasdaqCM: SNCE) to eMed, LLC. Under the terms of the proposed transaction, shareholders of Science 37 will receive $5.75 in cash for each share of Science 37 that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether.

SCIENCE 37 HOLDINGS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Science 37 Holdings, Inc. - SNCE

eMed commences tender offer for Science 37

MIAMI , Feb. 12, 2024 /PRNewswire/ -- eMed, LLC ("eMed") today announced that its wholly-owned subsidiary, Marlin Merger Sub Corporation, a Delaware corporation ("Purchaser"), has commenced a cash tender offer to purchase all the outstanding shares of common stock, par value $0.0001 per share, of Science 37 Holdings, Inc. (NASDAQ: SNCE) ("Science 37") for a price of $5.75 per share (the "Offer"). The Offer is being made upon the terms and subject to the conditions set forth in the Offer to Purchase, dated February 12, 2024 and the related Letter of Transmittal and pursuant to the terms of the previously announced Agreement and Plan of Merger, dated as of January 28, 2024 (the "Merger Agreement"), among eMed, Purchaser and Science 37.

eMed commences tender offer for Science 37

See News Rankings

Charts implemented using Lightweight Charts™